In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: Implications for ventricular remodelling

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 9, 2005, Pages 697-701

  Martin, Jennifer ^a,b   Denver, Rachel ^a   Bailey, Michael ^a   Krum, Henry ^a  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Fibrosis; Inflammation; Statin

Indexed keywords

ANGIOTENSIN; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; ANGIOTENSIN II; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; HEPTANOIC ACID DERIVATIVE; IMMEDIATE EARLY PROTEIN; PROCOLLAGEN; PYRROLE DERIVATIVE; SIGNAL PEPTIDE; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; GENE EXPRESSION; HEART VENTRICLE REMODELING; INFLAMMATION; NONHUMAN; RAT; STATISTICAL ANALYSIS; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; HEART; HEART MUSCLE; HUMAN; METABOLISM; PHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; FIBROBLASTS; HEART; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCARDIUM; PROCOLLAGEN; PYRROLES; RATS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

EID: 26944458567     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2005.04256.x     Document Type: Article

References (24)

1. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur. J. Pharmacol. 2000; 410: 83-92.
2. Holm T, Andreassen AK, Ueland T et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am. J. Cardiol. 2001; 87: 815-18.
3. Park JK, Muller DN, Mervaala EM et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000; 58: 1420-30.
4. Porter K, Turner N, O'Regan D. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: Inhibition by simvastatin. Cardiovasc. Res. 2004; 64: 507-15.
5. Camellitia P, Borgb T, Kohla P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005; 65: 40-51.
6. Bauersachs J, Galuppo P, Fracarollo D et al. Improvement of left ventricular remodelling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001; 104: 982-7.
7. Hayashidani S, Tsutsui H, Shiomi T et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-73.
8. Tian J, Zhao L, Zhang H et al. Effects of atorvastatin on the proliferation and collagen synthesis of rat cardiac fibroblasts. Zhonghua Yi Xue Za Zhi 2003; 83: 118-22.
9. Hannan R, Luyken J, Rothblum L. Regulation of ribosomal DNA transcription during contraction-induced hypertrophy of neonatal cardiomyocytes. J. Biol. Chem. 1996; 271: 3213-20.
10. Tzanidis A, Hannan R, Thomas W et al. Direct actions of urotensin II on the heart: Implications for cardiac fibrosis and hypertrophy. Circ. Res. 2003; 93: 246-53.
11. Ruperez M, Lorenzo O, Blanco-Colio L, Esteban V, Egido J, Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003; 108: 1499-505.
12. Sporn M, Roberts A. Transforming growth factor-beta: Recent progress and new challenges. J. Cell Biol. 1992; 119: 1017-21.
13. Koh KK. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability. Cardiovasc. Res. 2000; 47: 648-57.
14. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br. J. Pharmacol. 2001; 133: 1172-80.
15. Su S, Hsiao C, Chu C et al. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am. J. Cardiol. 2000; 86: 514-18.
16. Horwich T, Hamilton M, MacLeilan R et al. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J. Am. Coll. Cardiol. 2004; 43: 642-8.
17. Node K, Fujita M, Kitakaze M et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108: 839-43.
18. Ortego M, Bustos C, Hernandez-Presa MA et al. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-61.
19. Hahn A, Heusinger-Ribeiro J, Lanz T et al. Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by rho proteins and the actin cytoskeleton. J. Biol. Chem. 2000; 275: 37 429-35.
20. Wolfrum S, Dendorfer A, Schutt M et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphoatidylinositide 3-kinase/Akt pathway. J. Cardiovasc. Pharmacol. 2004; 44: 348-55.
21. 1 receptor expression Rac1 GTPase. Mol. Pharmacol. 2001; 59: 646-54.
22. Ichiki T, Takeda K, Tokunou T et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1896-901.
23. Spinale F, Peterson J. Introduction to special issue on the matrix metalloproteinases: New insights into myocardial remodeling. Heart Fail. Rev. 2004; 9: 5-6.
24. Krum H, McMurray J. Statins and chronic heart failure: Do we need a largescale outcome trial? J. Am. Coll. Cardiol. 2002; 39: 1567-73.